BEIJING, March 25, 2024/PRNewswire/ -- Baiaosetu (Beijing) Pharmaceutical Technology Co., Ltd. (“BEIJING”, stock code 02315.HK), an international biotechnology company with innovative technology that drives the development of new antibody-like drugs, today announced a partnership with ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean biotech company that develops novel therapeutics for tumors and central nervous system diseases in the clinical phase to jointly develop novel bispecific antibody-conjugated drugs (dual-antibody ADC).
Baosetu RenLiteThe mouse platform can produce whole-human antibodies that recognize different epitopes and have high affinity. The platform features the generation of common light chain antibodies, so that the development of dual-antibody ADCs has design flexibility, simple production processes, and good pharmacogenicity. Based on this platform, future cooperation between the two parties may expand to different forms of ADC drug development.
Chairman of Baiosetu andCEO Dr. Shen Yuelei“We are delighted to have partnered with ABL,” he said. ABL has an advanced cancer immunotherapy and central nervous system disease therapy platform. They have continued to successfully advance pipeline research and development, demonstrating their expertise and capabilities in regulation, clinical development, and business development. RenLitePlatform-derived dual-antibody ADC drugs have shown better efficacy in various tumor models and have good safety. We believe that our dual-antibody ADC platform technology, which has high tumor selectivity, target co-entanglement, and simple CMC development, will effectively complement the advantages of ABL. Together, we will accelerate the development of novel dual-antibody ADC therapies.”
ABL CEO Sang Hoon LeeHe said, “We are very excited to cooperate with Baiosetu to jointly develop a dual-antibody ADC. This collaboration is an important step in our efforts to develop dual-antibody ADC drugs. We look forward to a fruitful collaboration and believe it will help us develop a differentiated pipeline and ultimately develop novel therapies that improve patients' quality of life.”
About Biosetto
Baiosetu (stock code: 02315.HK) is an international biotechnology company that drives the development of new drugs through innovative technology, and is committed to becoming a global birthplace of new drugs. Based on underlying gene editing technology, Baiosetu independently developed renMice(RenMAB, RenLite, Rennano, RentCR-mimic) Platform for the discovery of whole-human therapeutic monoclonal antibodies, bis/polyspecific antibodies, dual anti-ADC, nanoantibodies, and TCR-like antibodies. Bioosetu is developing large-scale drugs for more than 1,000 potential drug-forming targets (“Thousand Mouse Antibiotics”“Plan), and has established a library of more than 400,000 whole-human antibody sequences for global cooperation. As of June 30, 2023, Baiosetu has signed 50 cooperative drug development/licensing/transfer agreements and reached 42 target projects, renMICE, with companies including multiple MNCsThe platform authorized development cooperation; several clinical-stage antibody molecules have also reached external licensing cooperation. Company sub-brand BioIceIt provides thousands of gene-edited animal and cell models, including targeted humanized mice, and also provides preclinical pharmacological efficacy and gene editing services to customers around the world. Biosetou is headquartered in Beijing and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco), and Heidelberg, Germany. For more information, visit the official website.
regardingABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company focusing on tumor immunity and antibody therapy development for neurodegenerative diseases. Based on independent research and global cooperation, ABL has developed various dual-antibody platforms, such as Grabody-T and Grabody-B, and established an innovative pipeline composed of various clinical and pre-clinical drug candidate molecules. In the field of oncology, we have developed a modular 4-1bB adapter platform, Grabody-T, which has shown excellent efficacy and safety. In the field of neurodegenerative diseases, we have developed a Grabody-B that maximizes crossing the blood-brain barrier. Grabody-B is suitable for different central nervous system targets in a variety of neurological diseases, and has the potential to bring about breakthroughs in highly unmet medical needs in neurodegenerative diseases. For more information, please visit.